Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
A economic research study shows that oncologists' prescribing habits change after they've been visited by pharmaceutical sales reps — and it also shows the changes do not extend patients' lives.
-
As a shortage of growth hormone used to treat rare diseases in children drags on, families and doctors are struggling with insurers' requirements to get prescriptions filled. -
Drugmakers make big profits in the U.S. But many pay taxes far below the 21% corporate tax rate. Pfizer's effective tax rate is so low it's getting a big refund despite booking $59 billion in revenue.
-
OPill, the first over-the-counter birth control pill available without a prescription, is shipping to retailers nationwide.
-
Opill, an over-the-counter birth control pill, goes on sale online today. The pill is expected to be available in stores within a few weeks. -
The online pharmacy of entrepreneur Mark Cuban is adding two brand new Bayer drugs to its disruptor model, which relies on a radical transparency compared to the rest of the industry.
-
The Senate HELP committee questioned pharmaceutical CEOs about how much more Americans pay for the same drugs sold for less in Canada, Japan and Europe. -
Drugmaker Biogen is pulling the plug on its controversial Alzheimer's drug Aduhelm, following disappointing sales. It had been expected to be a blockbuster product.
-
Spoiler: There are some decreases this year, too. Here's an overview of the changing prices and what to make of them. -
January is when drug makers typically hike their prices. This year, there's a mixed bag of price increases and a few notable declines, such as on some forms of insulin.
